Drug Development

Articles

The multi-year agreement will give Novartis access to AbCellera’s expertise and state-of-the-art antibody discovery technology for up to ten clinically-relevant disease targets.

Novartis, AbCellera in Antibody Discovery Pact

The companies will use a $4.4-million grant from the National Institute of Allergy and Infectious Diseases to discover sustainable alternatives to shark squalene to use as vaccine adjuvants.

Amyris, IDRI to Engineer Molecules for Vaccine Adjuvant Applications

C-Bridge Capital will form a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis’ next-generation biosimilars in China.

Samsung Bioepis and C-Bridge Capital to Commercialize Biosimilars in China

Researchers used magnesium particles as tiny motors to deliver an oral vaccine against the bacterial pathogen Staphylococcus aureus.

Micromotors Deliver Oral Vaccines

The agency recommended six medicines for approval at its January 2019 meeting, including treatments for lung cancer, HIV-1, and autoimmune disorders.

EMA Approves Two Biosimilars and Two Generic Drugs

The US Pharmacopeial Convention’s new plan will include new and revised quality standards and activities to support the development of new generic drugs. 

USP’s Generics Access Plan to Encourage Competition

Marc Brown, PhD, is chief scientific officer and co-founder of MedPharm.

Sarah Pratt is chief operating officer at MedPharm.

Christopher Harrison, is head of Process Development and Manufacture at MedPharm.

Using a QbD approach in the development and formulation of topical products will enable the drug developer to provide a robust control strategy for manufacturing.

Process Development Best Practices for Topical Drug Products

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

New platform technologies, advanced modeling tools, and addressing patient needs are important developments.

Advances in Engineering of Protein-Based APIs

Martin Koeberle is head of Analytical Development & Stability Testing, HERMES PHARMA-a division of Hermes Arzneimittel GmbH.

The challenge of achieving sustained delivery of an active ingredient or nutrient can be achieved with extended-release formulations.

A User-Friendly Approach to Developing an Extended-Release Product

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Biosimilars, pricing strategies, and technology will influence growth in spending on drugs. 

Formulation and Drug Delivery